Published in J Med Case Rep on November 29, 2007
Sexual orientation disparities in cancer-related risk behaviors of tobacco, alcohol, sexual behaviors, and diet and physical activity: pooled Youth Risk Behavior Surveys. Am J Public Health (2013) 1.26
Esophageal cancer in young people: a case series of 109 cases and review of the literature. PLoS One (2010) 1.21
Risk of oesophageal cancer among patients previously hospitalised with eating disorder. Cancer Epidemiol (2015) 0.76
Disparities by Sexual Orientation in Frequent Engagement in Cancer-Related Risk Behaviors: A 12-Year Follow-Up. Am J Public Health (2016) 0.76
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol (2001) 6.07
Delays in the diagnosis of oesophagogastric cancer: a consecutive case series. BMJ (1997) 5.02
The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med (1985) 4.30
The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA (1995) 2.68
Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med (2000) 1.83
Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg (2006) 1.47
Epidemiology of the eating disorders. Psychiatr Clin North Am (1996) 1.18
Recent changes in the epidemiology of esophageal cancer. Surg Oncol (2001) 0.98
Heredity and risk of cancer of the esophagus and gastric cardia. Cancer Epidemiol Biomarkers Prev (2000) 0.97
Bulimia nervosa complicated by Barrett's esophagus and esophageal cancer. Gastrointest Endosc (1996) 0.84
Bulimia nervosa as a risk factor for squamous cell carcinoma of the esophagus? Am J Gastroenterol (2003) 0.84
Bulimia: medical complications. J Womens Health (Larchmt) (2004) 0.84
Barrett esophagus. Ann Intern Med (1991) 0.83
Bulimia and gastric cancer. Ann Intern Med (1985) 0.82
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
The impact of radiation therapy sequencing on survival and cardiopulmonary mortality in the combined modality treatment of patients with esophageal cancer. Cancer (2013) 1.97
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol (2003) 1.88
Clinical trial resources on the internet must be designed to reach underrepresented minorities. Cancer J (2007) 1.56
Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. Cancer J (2007) 1.50
Internet-based survey evaluating use of pain medications and attitudes of radiation oncology patients toward pain intervention. Int J Radiat Oncol Biol Phys (2008) 1.46
Adult cancer survivorship: evolution, research, and planning care. CA Cancer J Clin (2009) 1.35
An internet tool for creation of cancer survivorship care plans for survivors and health care providers: design, implementation, use and user satisfaction. J Med Internet Res (2009) 1.27
Complementary and alternative medicine and supportive care at leading cancer centers: a systematic analysis of websites. J Altern Complement Med (2010) 1.19
Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer (2010) 1.18
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res (2013) 1.16
Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res (2005) 1.12
Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol (2008) 1.12
Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.10
Advanced local therapies for the treatment of limited systemic mCRC. Oncology (Williston Park) (2014) 1.07
Patient reported late effects of gynecological cancer treatment. Gynecol Oncol (2011) 1.03
Breast cancer patients' attitudes toward clinical trials in the radiation oncology clinic versus those searching for trial information on the Internet. Breast J (2006) 1.02
Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer (2014) 1.02
The influence of race on the attitudes of radiation oncology patients towards clinical trial enrollment. Am J Clin Oncol (2006) 1.01
Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer (2010) 0.98
Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer (2014) 0.98
Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys (2009) 0.98
High level use and satisfaction with internet-based breast cancer survivorship care plans. Breast J (2011) 0.97
Impact of internet-based cancer survivorship care plans on health care and lifestyle behaviors. Cancer (2013) 0.97
Cosmetic outcomes and complications reported by patients having undergone breast-conserving treatment. Int J Radiat Oncol Biol Phys (2011) 0.95
Adjuvant radiotherapy for completely resected stage 2 thymoma. Cancer (2011) 0.90
Cancer patient attitudes toward analgesic usage and pain intervention. Clin J Pain (2012) 0.90
Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor. Gastrointest Endosc (2005) 0.89
Palliative care in the management of lung cancer: analgesic utilization and barriers to optimal pain management. J Opioid Manag (2012) 0.86
Utilization of internet-based survivorship care plans by lung cancer survivors. Clin Lung Cancer (2009) 0.86
An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer. Radiat Oncol (2013) 0.86
Isocitrate dehydrogenase-1 is mutated in inflammatory bowel disease-associated intestinal adenocarcinoma with low-grade tubuloglandular histology but not in sporadic intestinal adenocarcinoma. Am J Surg Pathol (2014) 0.84
Rates of unconventional medical therapy use in patients with prostate cancer: standard history versus directed questions. Urology (2002) 0.84
Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability. Am J Surg Pathol (2016) 0.83
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study. Am J Clin Oncol (2011) 0.82
Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future. Curr Treat Options Oncol (2014) 0.82
The role of radiation therapy in malignant thymoma: a Surveillance, Epidemiology, and End Results database analysis. J Thorac Oncol (2010) 0.82
Developments in treatment of esophageal/gastric cancer. Curr Treat Options Oncol (2009) 0.81
Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research. Value Health (2013) 0.80
Feasibility of electromagnetic transponder use to monitor inter- and intrafractional motion in locally advanced pancreatic cancer patients. Int J Radiat Oncol Biol Phys (2011) 0.80
Brachytherapy in the treatment of cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2010) 0.80
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol (2013) 0.80
High-dose-rate (HDR) brachytherapy for the treatment of benign obstructive endobronchial granulation tissue. Int J Radiat Oncol Biol Phys (2006) 0.79
Hepatocellular carcinoma: prevention and therapy. Curr Oncol Rep (2011) 0.79
Trends in the use of postoperative radiation therapy in patients with localized resectable pancreatic cancer. Am J Clin Oncol (2012) 0.79
Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management. Clin Colorectal Cancer (2006) 0.79
Proton therapy in adjuvant treatment of gastric cancer: planning comparison with advanced x-ray therapy and feasibility report. Acta Oncol (2014) 0.78
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer (2013) 0.78
Primary ductal adenocarcinoma of the lacrimal gland. Ophthalmology (2005) 0.78
Applicability of randomized trials in radiation oncology to standard clinical practice. Cancer (2013) 0.78
Intraperitoneal photodynamic therapy causes a capillary-leak syndrome. Ann Surg Oncol (2003) 0.77
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Clin Cancer Res (2002) 0.77
Dose perturbations by electromagnetic transponders in the proton environment. Phys Med Biol (2013) 0.77
Chemoradiotherapy in the treatment of rectal cancer. Hematol Oncol Clin North Am (2002) 0.77
Nursing resources: preparing patients for life after cancer treatment. Am J Nurs (2011) 0.77
Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival. Am J Surg Pathol (2015) 0.77
BRAF V600E is also seen in unclassifiable splenic B-cell lymphoma/leukemia, a potential mimic of hairy cell leukemia. Blood (2013) 0.76
Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer: Is There an Optimal Succession? Oncology (Williston Park) (2016) 0.76
The importance of a preclinical trial: a selected injury intervention program for pediatric trauma centers. J Trauma (2008) 0.76
Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy. Acta Oncol (2015) 0.76
A brief summary of alcohol intervention research at West Virginia University from 1998-2003. W V Med J (2004) 0.76
Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer. Cancer (2003) 0.75
Recent advances in colorectal cancer therapy. Cancer Biol Ther (2003) 0.75
Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma? Nat Clin Pract Oncol (2008) 0.75
Recombinant human granulocyte macrophage colony stimulating factor in deep second-degree burn wound healing. Medicine (Baltimore) (2017) 0.75
The utilization of oncology web-based resources in Spanish-speaking Internet users. Am J Clin Oncol (2012) 0.75
Adjuvant therapy for gastric cancer: how negative results can help patients. J Natl Cancer Inst (2007) 0.75
Cancers of the large bowel and hepatobiliary tract. Cancer Chemother Biol Response Modif (2005) 0.75
General assessment of the patient with cancer for the interventional oncologist. J Vasc Interv Radiol (2006) 0.75
Abdominal and pancreatic motion correlation using 4D CT, 4D transponders, and a gating belt. J Appl Clin Med Phys (2013) 0.75
Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas. Cancer Chemother Pharmacol (2010) 0.75
Palliative radiation therapy in oncology. Anesthesiol Clin (2006) 0.75
What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy? Expert Rev Anticancer Ther (2011) 0.75